When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.
The National Cancer Institute-led team used a CRISPR-based approach to identify genes like APLNR that, when mutated, make cancers resistant to immunotherapy.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The agencies said they're aiming to "accelerate the development of proteogenomic technologies and biomarkers, as it relates to precision medicine in cancer."
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
